FORT MYERS, Fla. and LOS ANGELES, Sept. 20, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, LLC ("AON" or the "Company"), a rapidly growing network of community-based oncology practices, and Digital Transformation Opportunities Corp. (NASDAQ:DTOC) ("DTOC"), a special purpose acquisition company focused on the healthcare industry, announced today the completion of their previously announced business combination (the "Business Combination"). The combined company has been renamed American Oncology Network, Inc., and its common stock is expected to commence trading on the Nasdaq Stock Market LLC ("Nasdaq") under the new ticker symbol "AONC" on September 21, 2023. The Business Combination

TORONTO, Jan. 11, 2023 /CNW/ - D2L Inc. (TSX:DTOL) ("D2L" or the "Company"), a leading global learning technology company, today announced the appointment of technology executive Heather Zynczak to its Board of Directors. Zynczak spent the past 25 years in marketing, product and revenue leadership positions in technology. She was most recently Chief Marketing Officer of Pluralsight (NASDAQ:PS), where she was responsible for all aspects of marketing and digital revenue. During her tenure at Pluralsight, the company grew B2B revenue over 50% year-over-year, expanding revenue to

American Oncology Network (AON) is a rapidly growing network of community-based oncology practices The proposed transaction values the combined company at a pro forma enterprise value of approximately $500 million American Oncology Network ("AON" or the "Company"), a rapidly growing network of community-based oncology practices, and Digital Transformation Opportunities Corp. (NASDAQ:DTOC) ("DTOC"), a special purpose acquisition company focused on the healthcare industry, today announced that they have entered into a definitive business combination agreement pursuant to which AON will become a public company (the "Business Combination"). Upon completion of the Business Combination, the

4/A - American Oncology Network, Inc. (0001839998) (Issuer)

3/A - American Oncology Network, Inc. (0001839998) (Issuer)

4 - American Oncology Network, Inc. (0001839998) (Issuer)

424B5 - American Oncology Network, Inc. (0001839998) (Filer)

EFFECT - American Oncology Network, Inc. (0001839998) (Filer)

S-8 - American Oncology Network, Inc. (0001839998) (Filer)

TORONTO, Jan. 11, 2023 /CNW/ - D2L Inc. (TSX:DTOL) ("D2L" or the "Company"), a leading global learning technology company, today announced the appointment of technology executive Heather Zynczak to its Board of Directors. Zynczak spent the past 25 years in marketing, product and revenue leadership positions in technology. She was most recently Chief Marketing Officer of Pluralsight (NASDAQ:PS), where she was responsible for all aspects of marketing and digital revenue. During her tenure at Pluralsight, the company grew B2B revenue over 50% year-over-year, expanding revenue to

SC 13D - American Oncology Network, Inc. (0001839998) (Subject)

SC 13D/A - American Oncology Network, Inc. (0001839998) (Subject)

SC 13D - American Oncology Network, Inc. (0001839998) (Subject)